Starton is planning larger Phase II trials for chronic lymphocytic leukaemia (CLL) and multiple myeloma in 2025. Credit: Ground Picture via Shutterstock.

Starton Therapeutics has successfully demonstrated the use of BD’s on-body injector technology to deliver its low-dose lenalidomide formulation called STAR-LLD.

An on-body injector is a wearable device that delivers medication continuously under the skin through a tiny needle. It sticks to the body, allowing patients to receive controlled doses over time while going about their daily activities.  

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The BD Evolve on-body injector administers cancer drug STAR-LLD (lenalidomide) continuously and at a low dose through the skin, rather than taking it in pill form, which is called Revlimid (lenalidomide). Starton successfully tested this device to establish whether it can deliver the STAR-LLD formulation at a consistent, low dose. 

Earlier this year, Starton announced positive early results from its Phase Ib trial (NCT06087653) in patients with multiple myeloma. The trial, which met all of its primary and secondary endpoints, evaluated STAR-LLD continuous subcutaneous (SC) delivery compared to once-daily Revlimid oral delivery. The company is now planning larger Phase II trials for chronic lymphocytic leukaemia (CLL) and multiple myeloma in 2025.  

Starton’s CEO Pedro Lichtinger said: “The positive results from this study enable us to expand the use of STAR-LLD, which is expected to lead to improved quality of life for patients undergoing lenalidomide treatment.

“We believe the on-body technology provides the convenience, comfortability, and patient/oncologist acceptability for significantly increasing the number of patients that can benefit from STAR-LLD.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Founded in 2017, Starton’s transdermal technology can enhance approved drugs’ efficacy, making them more tolerable and potentially useable for other indications. According to GlobalData analysis, the company is one of the key players in the active development of transdermal drug delivery.

GlobalData is the parent company of Clinical Trials Arena.

Another key player identified in the space is UK-based Medherant, which uses its TEPI patch technology to deliver a range of already-approved drugs. The company is currently developing a testosterone patch for postmenopausal women, which would be the first and only product of its kind on the market.

Other companies identified as key players in the active development of transdermal drug delivery include 4P Therapeutics, MEDRx, Nemaura Pharma, Sinsin Pharmaceutical, and Icure Pharmaceutical.